Drug Development Licensing Pharmaceutical Companies RNA 
Drug Discovery World
OCTOBER 16, 2023
A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. Cambridge is a focal point for many pharmaceutical companies working in this therapeutic area.
Drug Discovery World
MARCH 7, 2023
She has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing. Hu was formerly a consultant at McKinsey & Company where she advised pharmaceutical companies on strategic, operational and organizational issues.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 8, 2020
AbCellera’s AI-powered antibody discovery platform speeds the otherwise lengthy and grueling process by analyzing the database of natural immune systems to find antibodies that can be developed into drugs. Tackle the toughest problems in drug development.” The promise to partners is to “move quickly. Reduce cost.
The Pharma Data
SEPTEMBER 8, 2020
About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we’re creating a future where disease is a thing of the past. About Moderna Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Learn more at Learn more at www.jnj.com.
The Pharma Data
SEPTEMBER 8, 2020
About the Janssen Pharmaceutical Companies of. We’re the Pharmaceutical Companies of. is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Forward-Looking Statement of the Janssen Pharmaceutical Companies of. Learn more at Learn more at.
Codon
SEPTEMBER 29, 2024
But, regardless of which was first, they all operated with the same core data as their mechanism for understanding life: messenger RNA ( mRNA ). It wasn’t a silver bullet to the hard problem of drug development, but it wasn’t too far off either. There was scFormer in 2022, scGPT in 2023, and plenty of others.
The Pharma Data
OCTOBER 27, 2020
Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19. The company has compounds in various stages of clinical and preclinical development with a focus on oncology.
Expert insights. Personalized for you.
189 
Let's personalize your content